Safe Sermorelin

Research digest / references

Sermorelin references

Every figure on this site routes back to one of these sources — trials, pharmacokinetic studies, and reviews on GHRH(1-29) and its analogs, each with a DOI and PubMed link.

Read the safety recordBack to the overview

How to read this list

These are the primary sources cited across the site. Where a body-composition or cognition figure comes from the related GHRH analog tesamorelin rather than from sermorelin itself, that is noted in the page text — the citation here is to the study as published. Each entry carries a DOI and a PubMed link so the original can be read in full.

  1. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. ↗
  2. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. ↗
  3. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. ↗
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. ↗
  5. Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. ↗
  6. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. ↗
  7. Vijayakumar A, et al. Role of pulsatile growth hormone (GH) secretion in the regulation of lipolysis in fasting humans. Clin Diabetes Endocrinol. 2022;8(1):1. ↗
  8. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. ↗
  9. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9. ↗
  10. Veldhuis JD, Bowers CY. Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp. J Clin Endocrinol Metab. 2009;94(7):2544-50. ↗
  11. Falutz J. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. ↗
  12. Vitiello MV, Moe KE, Merriam GR, et al. Treating age-related changes in somatotrophic hormones, sleep, and cognition. Dialogues Clin Neurosci. 2001;3(3):229-236. ↗
  13. Schier T, Guldner J, Colla M, et al. Changes in sleep-endocrine activity after growth hormone-releasing hormone depend on time of administration. J Neuroendocrinol. 1997;9(3):201-205. ↗
  14. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗
  15. Verges B, et al. GHRH in diabetes and metabolism. Rev Endocr Metab Disord. 2025. ↗